1. Feng, Mengdie, Xie, Xueqin, Han, Guoqiang, Chen, Jianjun, Zhang, Haojian. . YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. In Blood, 138, 71-85. doi:10.1182/blood.2020009676. https://pubmed.ncbi.nlm.nih.gov/33763698/
2. Xiao, Ye, Cai, Guang-Ping, Feng, Xu, Zheng, Yong-Jun, Yang, Mi. 2023. Splicing factor YBX1 regulates bone marrow stromal cell fate during aging. In The EMBO journal, 42, e111762. doi:10.15252/embj.2022111762. https://pubmed.ncbi.nlm.nih.gov/36943004/
3. Jayavelu, Ashok Kumar, Schnöder, Tina M, Perner, Florian, Mann, Matthias, Heidel, Florian H. 2020. Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. In Nature, 588, 157-163. doi:10.1038/s41586-020-2968-3. https://pubmed.ncbi.nlm.nih.gov/33239784/
4. Liu, Liwen, Chen, Yu, Zhang, Tao, Xue, Wenhua, Sun, Ranran. 2024. [Not Available]. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11, e2302379. doi:10.1002/advs.202302379. https://pubmed.ncbi.nlm.nih.gov/38566431/
5. Liu, Boqiang, Shen, Hao, He, Jing, Shi, Liang, Cai, Xiujun. 2023. Cytoskeleton remodeling mediated by circRNA-YBX1 phase separation suppresses the metastasis of liver cancer. In Proceedings of the National Academy of Sciences of the United States of America, 120, e2220296120. doi:10.1073/pnas.2220296120. https://pubmed.ncbi.nlm.nih.gov/37459535/
6. Meng, Huangyang, Miao, Huixian, Zhang, Yashuang, Zhang, Lin, Cheng, Wenjun. 2024. YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification. In Cancer letters, 597, 217064. doi:10.1016/j.canlet.2024.217064. https://pubmed.ncbi.nlm.nih.gov/38880223/
7. Lin, Chunlin, Lin, Penghang, Yao, Hengxin, Ye, Jianxin, Zhu, Guangwei. 2024. Modulation of YBX1-mediated PANoptosis inhibition by PPM1B and USP10 confers chemoresistance to oxaliplatin in gastric cancer. In Cancer letters, 587, 216712. doi:10.1016/j.canlet.2024.216712. https://pubmed.ncbi.nlm.nih.gov/38364962/
8. Lim, Jia Pei, Shyamasundar, Sukanya, Gunaratne, Jayantha, Matsumoto, Ken, Bay, Boon Huat. 2017. YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro. In BMC cancer, 17, 201. doi:10.1186/s12885-017-3187-7. https://pubmed.ncbi.nlm.nih.gov/28302118/
9. Li, Borui, Xing, Faliang, Wang, Jingyi, Qin, Yi, Li, Zheng. 2024. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. In Cancer letters, 602, 217197. doi:10.1016/j.canlet.2024.217197. https://pubmed.ncbi.nlm.nih.gov/39216548/
10. Yao, Bing, Xing, Mengying, Zeng, Xiangwei, Zhao, Quan, Ma, Changyan. . KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc. In Clinical and translational medicine, 14, e1753. doi:10.1002/ctm2.1753. https://pubmed.ncbi.nlm.nih.gov/38967349/
智鼠故事 
